Cargando…

The efficacy of single pharmacist medication review among type II diabetic patients who take six chronic medications or more: a case–control study

BACKGROUND: Pharmacist medication review has been implemented in many health organizations throughout the world in an attempt to alleviate the underlying risk of polypharmacy in elderly patients. These consultations are often frequent and prolonged, and are thus associated with increased costs. To d...

Descripción completa

Detalles Bibliográficos
Autores principales: Harmatz, Danielle, Vinker, Shlomo, Wagner, Talia, Raveh, Tal, Merzon, Eugene, Cohen, Avivit Golan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896278/
https://www.ncbi.nlm.nih.gov/pubmed/35241170
http://dx.doi.org/10.1186/s13584-022-00513-0
_version_ 1784663128393383936
author Harmatz, Danielle
Vinker, Shlomo
Wagner, Talia
Raveh, Tal
Merzon, Eugene
Cohen, Avivit Golan
author_facet Harmatz, Danielle
Vinker, Shlomo
Wagner, Talia
Raveh, Tal
Merzon, Eugene
Cohen, Avivit Golan
author_sort Harmatz, Danielle
collection PubMed
description BACKGROUND: Pharmacist medication review has been implemented in many health organizations throughout the world in an attempt to alleviate the underlying risk of polypharmacy in elderly patients. These consultations are often frequent and prolonged, and are thus associated with increased costs. To date, data regarding the most effective way to utilize pharmacist consultations for the improvement of health status is scant. AIM: To evaluate the effectiveness of a single pharmacist consultation on changes in chronic medication regimes and on selected outcomes of diabetes 1-year after the consultation. METHODS: A case–control study included an intervention group of 740 patients who had pharmacist consultations and a reference group of 1476 matched patients who did not have a pharmacist consultation. 1-year outcome measures were compared including changes in medications, improved safety, and objective variables such as Hba1c, blood pressure, and lipid profile. RESULTS: In the pharmacist consultation group, there were significantly more treatment changes ([mean 1.5 vs. 0.7, p < 0.001 medications were stopped], and [mean 1.3 vs. 0.4, p < 0.05 medications were started]). Patient safety improved with a general reduction in opiates and benzodiazepines ([50.0% vs. 31.6%, p < 0.05 opioids were stopped] and [58.8% vs 43.8%, p < 0.001 benzodiazepines were stopped]). Sulfonylurea treatment reduced (10.7% vs. 3.6%, p < 0.05 patients who stopped Sulfonylurea) and Glucagon-like peptide-1 receptor agonists (GLP-1) increased (16.4% vs. 11.2%, p < 0.001 patients who started GLP-1). Additionally, HbA1c levels showed a small decrease in the pharmacist consultation group ([− 0.18 ± 1.11] vs. [− 0.051 ± 0.80], p = 0.0058) but no significant differences were found regarding blood pressure or lipids profile. CONCLUSION: A single pharmacist consultation beneficially impacted specific clinical and patient safety outcomes. Pharmacist consultations may thus help resolve polypharmacy complexities in primary care.
format Online
Article
Text
id pubmed-8896278
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88962782022-03-14 The efficacy of single pharmacist medication review among type II diabetic patients who take six chronic medications or more: a case–control study Harmatz, Danielle Vinker, Shlomo Wagner, Talia Raveh, Tal Merzon, Eugene Cohen, Avivit Golan Isr J Health Policy Res Original Research Article BACKGROUND: Pharmacist medication review has been implemented in many health organizations throughout the world in an attempt to alleviate the underlying risk of polypharmacy in elderly patients. These consultations are often frequent and prolonged, and are thus associated with increased costs. To date, data regarding the most effective way to utilize pharmacist consultations for the improvement of health status is scant. AIM: To evaluate the effectiveness of a single pharmacist consultation on changes in chronic medication regimes and on selected outcomes of diabetes 1-year after the consultation. METHODS: A case–control study included an intervention group of 740 patients who had pharmacist consultations and a reference group of 1476 matched patients who did not have a pharmacist consultation. 1-year outcome measures were compared including changes in medications, improved safety, and objective variables such as Hba1c, blood pressure, and lipid profile. RESULTS: In the pharmacist consultation group, there were significantly more treatment changes ([mean 1.5 vs. 0.7, p < 0.001 medications were stopped], and [mean 1.3 vs. 0.4, p < 0.05 medications were started]). Patient safety improved with a general reduction in opiates and benzodiazepines ([50.0% vs. 31.6%, p < 0.05 opioids were stopped] and [58.8% vs 43.8%, p < 0.001 benzodiazepines were stopped]). Sulfonylurea treatment reduced (10.7% vs. 3.6%, p < 0.05 patients who stopped Sulfonylurea) and Glucagon-like peptide-1 receptor agonists (GLP-1) increased (16.4% vs. 11.2%, p < 0.001 patients who started GLP-1). Additionally, HbA1c levels showed a small decrease in the pharmacist consultation group ([− 0.18 ± 1.11] vs. [− 0.051 ± 0.80], p = 0.0058) but no significant differences were found regarding blood pressure or lipids profile. CONCLUSION: A single pharmacist consultation beneficially impacted specific clinical and patient safety outcomes. Pharmacist consultations may thus help resolve polypharmacy complexities in primary care. BioMed Central 2022-03-03 /pmc/articles/PMC8896278/ /pubmed/35241170 http://dx.doi.org/10.1186/s13584-022-00513-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Original Research Article
Harmatz, Danielle
Vinker, Shlomo
Wagner, Talia
Raveh, Tal
Merzon, Eugene
Cohen, Avivit Golan
The efficacy of single pharmacist medication review among type II diabetic patients who take six chronic medications or more: a case–control study
title The efficacy of single pharmacist medication review among type II diabetic patients who take six chronic medications or more: a case–control study
title_full The efficacy of single pharmacist medication review among type II diabetic patients who take six chronic medications or more: a case–control study
title_fullStr The efficacy of single pharmacist medication review among type II diabetic patients who take six chronic medications or more: a case–control study
title_full_unstemmed The efficacy of single pharmacist medication review among type II diabetic patients who take six chronic medications or more: a case–control study
title_short The efficacy of single pharmacist medication review among type II diabetic patients who take six chronic medications or more: a case–control study
title_sort efficacy of single pharmacist medication review among type ii diabetic patients who take six chronic medications or more: a case–control study
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896278/
https://www.ncbi.nlm.nih.gov/pubmed/35241170
http://dx.doi.org/10.1186/s13584-022-00513-0
work_keys_str_mv AT harmatzdanielle theefficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy
AT vinkershlomo theefficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy
AT wagnertalia theefficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy
AT ravehtal theefficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy
AT merzoneugene theefficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy
AT cohenavivitgolan theefficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy
AT harmatzdanielle efficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy
AT vinkershlomo efficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy
AT wagnertalia efficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy
AT ravehtal efficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy
AT merzoneugene efficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy
AT cohenavivitgolan efficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy